We are analyzing https://link.springer.com/article/10.1186/1471-2407-13-17.

Title:
Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations | BMC Cancer
Description:
Background Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view. On this regard, a new compound, dabrafenib (GSK2118436), has been demonstrated to be effective in patients carrying the BRAFV600E/K mutations. We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Telecommunications
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

melanoma, cell, braf, dabrafenib, article, lines, mutations, pubmed, data, patients, erk, google, scholar, cancer, ascierto, inhibition, authors, manuscript, treatment, cas, analysis, access, gene, proliferation, protein, activity, effects, privacy, cookies, open, paolo, view, gsk, effective, carrying, brafvdr, mapk, kinase, mutation, control, figure, author, information, publish, research, search, bmc, madonna, mozzillo, ribas,

Topics {✒️}

pre-publication history author information authors hospital-university health unit gabriele madonna open access article author correspondence braf/nras mutation frequencies innovative therapy mitogen-activated protein kinase inhibit cell growth erk signalling induced article download pdf m257 wild-type braf selective brafv600e inhibitor national research council bmc cancer 13 privacy choices/manage cookies fondazione melanoma onlus braf inhibitor melanoma cell lines effective targeted treatment clin cancer res pigment cell res phase iia trial authors’ original file preclinical melanoma models cell cycle progression cell numbers measured burker cell counts cultured melanoma cells western blot analysis wild-type braf braf mutational status total protein extracts presented strongly suggest remaining authors declare braf gene occur braf mutation-positive european economic area main content log view related subjects sustaining tumour maintenance total proteins extracted distinguishing clinicopathologic features bristol myers squibb brystol myers squibb braf-mutated targets prevalent braf mutation biomed central

Questions {❓}

Nissan MH, Solit DB: The “SWOT” of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
         description:Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view. On this regard, a new compound, dabrafenib (GSK2118436), has been demonstrated to be effective in patients carrying the BRAFV600E/K mutations. We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations. Three melanoma cell lines were tested: M257 wild-type BRAF, LCP BRAFV600R and WM266 BRAFV600D. The MTT assays were performed using standardized approaches. To evaluate the inhibition of MAPK pathway and the consequent inhibition of cellular proliferation, the phosphorylation of ERK was examined by Western Blot analysis performed on total protein extracts from cell lines after treatment with dabrafenib. Our experiments demonstrated an effective action of Dabrafenib (GSK2118436) and the inhibition of MAPK pathway in melanoma cell lines carrying BRAFV600D/R mutations. These results could be helpful to enlarge the number of melanoma patients who may benefit of a more effective targeted treatment.
         datePublished:2013-01-14T00:00:00Z
         dateModified:2013-01-14T00:00:00Z
         pageStart:1
         pageEnd:3
         license:https://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1471-2407-13-17
         keywords:
            BRAF inhibitor
            Dabrafenib
            Growth inhibition
            Melanoma therapy
            Cancer Research
            Oncology
            Surgical Oncology
            Health Promotion and Disease Prevention
            Biomedicine
            general
            Medicine/Public Health
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-13-17/MediaObjects/12885_2012_Article_3706_Fig1_HTML.jpg
         isPartOf:
            name:BMC Cancer
            issn:
               1471-2407
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Giusy Gentilcore
               affiliation:
                     name:Istituto Nazionale Tumori Fondazione Pascale
                     address:
                        name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gabriele Madonna
               affiliation:
                     name:Istituto Nazionale Tumori Fondazione Pascale
                     address:
                        name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nicola Mozzillo
               affiliation:
                     name:Istituto Nazionale Tumori Fondazione Pascale
                     address:
                        name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Antoni Ribas
               affiliation:
                     name:Jonsson Comprehensive Cancer Center, UCLA
                     address:
                        name:Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Antonio Cossu
               affiliation:
                     name:Hospital-University Health Unit (AOU)
                     address:
                        name:Department of Pathology, Hospital-University Health Unit (AOU), Sassari, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Giuseppe Palmieri
               affiliation:
                     name:National Research Council (ICB-CNR)
                     address:
                        name:Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Sassari, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Paolo A Ascierto
               affiliation:
                     name:Istituto Nazionale Tumori Fondazione Pascale
                     address:
                        name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
                        type:PostalAddress
                     type:Organization
                     name:Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola
                     address:
                        name:Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola, Naples, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
      description:Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view. On this regard, a new compound, dabrafenib (GSK2118436), has been demonstrated to be effective in patients carrying the BRAFV600E/K mutations. We here tested dabrafenib for its capability to inhibit cell growth on primary melanoma cell lines, established from patients' tumour tissues and carrying the BRAFV600D/R mutations. Three melanoma cell lines were tested: M257 wild-type BRAF, LCP BRAFV600R and WM266 BRAFV600D. The MTT assays were performed using standardized approaches. To evaluate the inhibition of MAPK pathway and the consequent inhibition of cellular proliferation, the phosphorylation of ERK was examined by Western Blot analysis performed on total protein extracts from cell lines after treatment with dabrafenib. Our experiments demonstrated an effective action of Dabrafenib (GSK2118436) and the inhibition of MAPK pathway in melanoma cell lines carrying BRAFV600D/R mutations. These results could be helpful to enlarge the number of melanoma patients who may benefit of a more effective targeted treatment.
      datePublished:2013-01-14T00:00:00Z
      dateModified:2013-01-14T00:00:00Z
      pageStart:1
      pageEnd:3
      license:https://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1471-2407-13-17
      keywords:
         BRAF inhibitor
         Dabrafenib
         Growth inhibition
         Melanoma therapy
         Cancer Research
         Oncology
         Surgical Oncology
         Health Promotion and Disease Prevention
         Biomedicine
         general
         Medicine/Public Health
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2F1471-2407-13-17/MediaObjects/12885_2012_Article_3706_Fig1_HTML.jpg
      isPartOf:
         name:BMC Cancer
         issn:
            1471-2407
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Giusy Gentilcore
            affiliation:
                  name:Istituto Nazionale Tumori Fondazione Pascale
                  address:
                     name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gabriele Madonna
            affiliation:
                  name:Istituto Nazionale Tumori Fondazione Pascale
                  address:
                     name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nicola Mozzillo
            affiliation:
                  name:Istituto Nazionale Tumori Fondazione Pascale
                  address:
                     name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Antoni Ribas
            affiliation:
                  name:Jonsson Comprehensive Cancer Center, UCLA
                  address:
                     name:Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Antonio Cossu
            affiliation:
                  name:Hospital-University Health Unit (AOU)
                  address:
                     name:Department of Pathology, Hospital-University Health Unit (AOU), Sassari, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Giuseppe Palmieri
            affiliation:
                  name:National Research Council (ICB-CNR)
                  address:
                     name:Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Sassari, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Paolo A Ascierto
            affiliation:
                  name:Istituto Nazionale Tumori Fondazione Pascale
                  address:
                     name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
                     type:PostalAddress
                  type:Organization
                  name:Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola
                  address:
                     name:Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola, Naples, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Cancer
      issn:
         1471-2407
      volumeNumber:13
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Istituto Nazionale Tumori Fondazione Pascale
      address:
         name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale Tumori Fondazione Pascale
      address:
         name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale Tumori Fondazione Pascale
      address:
         name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
         type:PostalAddress
      name:Jonsson Comprehensive Cancer Center, UCLA
      address:
         name:Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, USA
         type:PostalAddress
      name:Hospital-University Health Unit (AOU)
      address:
         name:Department of Pathology, Hospital-University Health Unit (AOU), Sassari, Italy
         type:PostalAddress
      name:National Research Council (ICB-CNR)
      address:
         name:Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Sassari, Italy
         type:PostalAddress
      name:Istituto Nazionale Tumori Fondazione Pascale
      address:
         name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
         type:PostalAddress
      name:Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola
      address:
         name:Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola, Naples, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Giusy Gentilcore
      affiliation:
            name:Istituto Nazionale Tumori Fondazione Pascale
            address:
               name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Gabriele Madonna
      affiliation:
            name:Istituto Nazionale Tumori Fondazione Pascale
            address:
               name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Nicola Mozzillo
      affiliation:
            name:Istituto Nazionale Tumori Fondazione Pascale
            address:
               name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
               type:PostalAddress
            type:Organization
      name:Antoni Ribas
      affiliation:
            name:Jonsson Comprehensive Cancer Center, UCLA
            address:
               name:Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Antonio Cossu
      affiliation:
            name:Hospital-University Health Unit (AOU)
            address:
               name:Department of Pathology, Hospital-University Health Unit (AOU), Sassari, Italy
               type:PostalAddress
            type:Organization
      name:Giuseppe Palmieri
      affiliation:
            name:National Research Council (ICB-CNR)
            address:
               name:Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Sassari, Italy
               type:PostalAddress
            type:Organization
      name:Paolo A Ascierto
      affiliation:
            name:Istituto Nazionale Tumori Fondazione Pascale
            address:
               name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
               type:PostalAddress
            type:Organization
            name:Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola
            address:
               name:Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola, Naples, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
      name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
      name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
      name:Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, USA
      name:Department of Pathology, Hospital-University Health Unit (AOU), Sassari, Italy
      name:Institute of Biomolecular Chemistry, National Research Council (ICB-CNR), Sassari, Italy
      name:Department Melanoma, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy
      name:Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Via Mariano Semmola, Naples, Italy

External Links {🔗}(67)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.93s.

LINK . SPRINGER . COM {}